Retatrutide is producing weight loss numbers that researchers did not expect to see this fast. The Phase 2 trial data published in the New England Journal of Medicine in 2023 showed participants losing up to 24.2% of their body weight over 48 weeks. That is not a rounding error. That is a number that changes how we think about obesity treatment.
Here is what the data actually shows, what it means for real people, and how retatrutide stacks up against everything else available right now. online personal trainer
What Is the Success Rate of Retatrutide for Weight Loss?
In the Phase 2 trial, participants on the highest dose of retatrutide (12 mg) lost an average of 24.2% of their total body weight over 48 weeks. The trial included 338 adults with obesity or overweight and no diabetes.
To put that in real terms, a person weighing 100 kg could expect to lose around 24 kg. That is not a small shift. That is a body composition change that affects blood pressure, joint load, metabolic markers, and energy levels in a measurable way.
Here is the breakdown by dose group from the trial:
- 4 mg dose group: average weight loss of 8.7%
- 8 mg dose group: average weight loss of 17.3%
- 12 mg dose group: average weight loss of 24.2%
- Placebo group: average weight loss of 2.1%
The 12 mg group also showed that 26% of participants lost 30% or more of their body weight. That is a result previously only seen with bariatric surgery.
What Percentage of Patients Respond to Retatrutide Treatment?
Response rates in the Phase 2 trial were high across all active dose groups. At the 12 mg dose, roughly 100% of participants lost at least some weight compared to placebo. More specifically, the trial reported that nearly all participants in the highest dose group achieved at least 5% weight loss, which is the clinical threshold used to define a meaningful response.
In my experience reviewing the GLP-1 literature, a 5% threshold response rate near 100% is unusual. Most weight loss drugs see a meaningful non-responder population. Retatrutide’s mechanism may explain why the response rate is so consistent.
Retatrutide works on three hormone receptors simultaneously. It activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. No other approved drug does all three. The glucagon receptor activation in particular drives energy expenditure, which means the body burns more calories even at rest. That triple action appears to reduce the number of people who simply do not respond.
How Does Retatrutide Compare to Semaglutide in Effectiveness?
Semaglutide at 2.4 mg (Wegovy) produces an average weight loss of around 14.9% over 68 weeks in the STEP 1 trial. Retatrutide at 12 mg produced 24.2% over 48 weeks. That is a larger result in a shorter time frame.
Direct head-to-head trials between retatrutide and semaglutide have not been completed yet. These are indirect comparisons across different trial populations, so they need to be read carefully. But the gap is large enough that it is hard to explain away with population differences alone.
Here is a side-by-side comparison based on available trial data:
- Semaglutide 2.4 mg (Wegovy): 14.9% average weight loss over 68 weeks, GLP-1 receptor agonist only
- Tirzepatide 15 mg (Zepbound/Mounjaro): 20.9% average weight loss over 72 weeks, dual GLP-1 and GIP agonist
- Retatrutide 12 mg: 24.2% average weight loss over 48 weeks, triple GLP-1, GIP, and glucagon agonist
What I found interesting in the data is that retatrutide appears to produce faster early weight loss than either semaglutide or tirzepatide. The rate of loss in the first 24 weeks was steeper. That matters for adherence because people who see results early tend to stay on treatment longer.
Is Retatrutide Effective for Type 2 Diabetes Management?
Yes. A separate Phase 2 trial published in 2023 tested retatrutide specifically in people with type 2 diabetes. The results showed significant reductions in HbA1c (a key marker of blood sugar control) alongside meaningful weight loss.
In that trial, participants with type 2 diabetes on the highest dose achieved:
- Average HbA1c reduction of 2.02 percentage points
- Average weight loss of 16.9% over 36 weeks
- A high proportion of participants reaching HbA1c below 7%, which is the standard clinical target
The weight loss in the diabetes population was lower than in the non-diabetes population, which is consistent with what we see across all GLP-1 class drugs. Insulin resistance and the metabolic environment in type 2 diabetes appear to blunt the weight loss response somewhat. But 16.9% is still a strong result, and the blood sugar improvements were clinically significant.
The glucagon receptor component of retatrutide is worth noting here. Glucagon raises blood sugar, so activating that receptor sounds counterproductive for diabetes. But at the doses used, the net effect on blood sugar is positive because the GLP-1 and GIP activity dominates, and the glucagon activation primarily drives fat burning rather than glucose release. The trial data confirms this plays out as expected.
What Are the Long-Term Success Rates of Retatrutide?
This is where honesty matters. The longest retatrutide data we have right now is 48 weeks from Phase 2. Phase 3 trials are underway, and those will run longer and include larger populations. We do not yet have 2-year or 5-year data.
What we can do is look at the trajectory. In the 48-week trial, weight loss had not plateaued by the end of the study in the highest dose group. That is different from semaglutide and tirzepatide, where weight loss typically levels off around 60 to 72 weeks. If retatrutide continues losing weight past 48 weeks, the final numbers could be higher than what Phase 2 showed.
What I saw in the data is that the weight loss curve was still descending at week 48 for the 12 mg group. That suggests the plateau had not been reached. Phase 3 will tell us where it lands.
The other long-term question is weight regain after stopping. With semaglutide, studies show people regain about two-thirds of lost weight within a year of stopping. There is no reason to expect retatrutide to behave differently. These drugs work while you take them. Stopping them removes the mechanism driving the result.
This is where combining medication with structured nutrition and training habits matters. The drug creates the caloric deficit and reduces appetite. Building sustainable habits during that window is what determines what happens after.
Has Retatrutide Been Approved by the FDA?
No. As of 2025, retatrutide has not received FDA approval. It is currently in Phase 3 clinical trials. Eli Lilly, the company developing it, has not yet submitted a New Drug Application to the FDA.
Phase 3 trials are larger and longer than Phase 2. They typically enroll thousands of participants across multiple countries and run for one to two years or more. The purpose is to confirm the Phase 2 results at scale, identify rare side effects, and establish long-term safety data.
Based on the Phase 2 results and the speed of Eli Lilly’s development timeline, analysts expect an FDA submission sometime in 2025 or 2026, with potential approval following 12 to 18 months after submission if the data holds. That is an estimate, not a guarantee.
Retatrutide is not currently available by prescription anywhere in the world through standard channels. Anyone claiming to sell it now is selling something unverified.
What Side Effects Affect the Success Rate?
Side effects matter because they drive discontinuation, and discontinuation ends results. In the Phase 2 trial, the most common side effects were gastrointestinal, the same pattern seen with semaglutide and tirzepatide.
Reported side effects included:
- Nausea (most common, particularly during dose escalation)
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite (this is also the mechanism, so it is both a side effect and the goal)
Discontinuation due to side effects in the Phase 2 trial was around 16% in the highest dose group. That is higher than semaglutide’s discontinuation rate in STEP 1, which was around 7%. The more aggressive weight loss may come with a higher side effect burden, particularly during the dose escalation phase.
What I found in reviewing the data is that most gastrointestinal side effects peaked during dose escalation and reduced once participants reached their maintenance dose. Slow titration appears to be the key to tolerability.
Three Ways to Think About Retatrutide That Most People Miss
Most coverage of retatrutide focuses on the weight loss number. Here are three angles that matter more for understanding what this drug actually does.
- The glucagon component changes the energy equation. GLP-1 drugs reduce appetite. Retatrutide does that and also increases energy expenditure through glucagon receptor activation. That means the caloric deficit comes from both sides, less intake and more burn. That is a different mechanism than anything currently approved, and it may explain why the weight loss numbers are higher.
- The plateau question is unresolved. Every weight loss drug hits a plateau. We do not know where retatrutide’s plateau is because Phase 2 ended before it was reached. The final weight loss number from Phase 3 could be higher than 24.2%, or the plateau could appear early in the extended timeline. This is the most important unknown in the current data.
- Muscle loss during rapid weight loss is a real concern. Losing 24% of body weight in 48 weeks is fast. Fast weight loss without resistance training and adequate protein intake leads to significant muscle loss alongside fat loss. The scale number looks good but the body composition outcome can be poor. Anyone using retatrutide or planning to use it needs a structured resistance training program and protein targets, not just the drug.
FAQ
What is the success rate of retatrutide compared to bariatric surgery?
Bariatric surgery produces average weight loss of 25 to 35% depending on the procedure. Retatrutide at 12 mg produced 24.2% in 48 weeks in Phase 2, with the curve still descending. Phase 3 data may close that gap further. Surgery remains more effective long-term for most patients, but retatrutide is the first drug to approach surgical outcomes.
Can you use retatrutide right now?
No. Retatrutide is not FDA approved and is not available by prescription. It is in Phase 3 trials. Do not purchase anything labeled as retatrutide from online sources. It is not verified.
Will retatrutide work without diet and exercise?
The Phase 2 trial included lifestyle counseling for all participants. The drug produced results in that context. Whether it works without any dietary or activity change is not tested. Based on how GLP-1 class drugs work, the drug reduces appetite and increases satiety, which naturally reduces caloric intake. But combining it with structured nutrition and resistance training produces better body composition outcomes than the drug alone.
How does retatrutide affect people who are not obese?
The Phase 2 trial enrolled people with a BMI of 27 or higher. There is no data on retatrutide in people with a BMI below 27. Using it outside the studied population is not supported by current evidence.
What happens to weight after stopping retatrutide?
Based on data from similar drugs, weight regain after stopping is significant. Semaglutide studies show roughly two-thirds of lost weight returns within 12 months of stopping. Retatrutide will likely follow a similar pattern. The drug manages the condition while you take it. It does not cure the underlying biology.
If you are working on your body composition and want to build the habits that hold results whether or not you are on medication, working with an online personal trainer gives you the structure to make that happen. The drug creates the window. What you build inside that window determines the long-term outcome.
